Annexon, Inc.

Special purpose acquisition corporations did not have a very successful run in the last SPAC wave to hit the life science sector, but a new round of the vehicles that provide companies an alternative

Follow-on public offerings (FOPOs) have become increasingly difficult to execute in the current financial market climate with public biopharmaceutical company valuations plummeting, so many drug devel

NTLA-2002 and 4D-150, which are single-dose, gene therapy candidates for hereditary angioedema and neovascular age-related macular degeneration (wet AMD) respectively, are among the latest products to

Apellis Pharmaceuticals, Inc. has been on a fast-growth trajectory driven by the launch of Syfovre (pegcetacoplan injection), the first drug approved by the US Food and Drug Administration for geogra